JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB267015

Human IRF2 knockout A549 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

IRF2 KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 4 and 7 bp deletion in exon 4. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
3 Images
Sanger Sequencing - Human IRF2 knockout A549 cell line (AB267015)
  • Sanger seq

Unknown

Sanger Sequencing - Human IRF2 knockout A549 cell line (AB267015)

Allele-1 : 7 bp deletion in exon4

Sanger Sequencing - Human IRF2 knockout A549 cell line (AB267015)
  • Sanger seq

Unknown

Sanger Sequencing - Human IRF2 knockout A549 cell line (AB267015)

Allele-2 : 1 bp insertion in exon 4.

Cell Culture - Human IRF2 knockout A549 cell line (AB267015)
  • Cell Culture

Lab

Cell Culture - Human IRF2 knockout A549 cell line (AB267015)

Representative images IRF2 knockout A549 cells, low and high confluency examples (top left and right respectively) and wild-type A549 cells, low and high confluency (bottom left and right respectively) showing typical adherent, epithelial-like morphology. Images were captured at 10X magnification using a EVOS M5000 microscope.

Key facts

Cell type

A549

Species or organism

Human

Tissue

Lung

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 4 and 7 bp deletion in exon 4

Disease

Carcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab267015-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255450 Human wild-type A549 cell line", "number":"AB267015-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab267015 Human IRF2 knockout A549 cell line", "number":"AB267015-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab267015-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255450 Human wild-type A549 cell line", "number":"AB267015-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab267015 Human IRF2 knockout A549 cell line", "number":"AB267015-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267015-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267015 Human IRF2 knockout A549 cell line", "number":"AB267015-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab267015-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab267015 Human IRF2 knockout A549 cell line", "number":"AB267015-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
IRF2
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
  • Do not allow the cell density to exceed 7x104 cells/cm2.
Culture medium

F-12K + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The Interferon Regulatory Factor 2 (IRF2) also known as IRF-2 plays an important role in cellular processes like modulation of immune responses and regulation of gene expression. It has a molecular mass of approximately 39 kDa. IRF2 is expressed across various tissues including the immune system cells fibroblasts and epithelial cells. It can function as both a transcriptional activator and repressor depending on the context and specific gene targets.
Biological function summary

IRF2 regulates immune responses by controlling the expression of interferon (IFN) responsive genes. It acts independently and as part of transcriptional complexes binding to specific DNA sequences within target genes. Its action prevents excessive activation of immune responses maintaining a balanced immune system. IRF2 also influences cell cycle regulation contributing to its role in cell growth and differentiation.

Pathways

And several cellular communication networks IRF2 is a central figure in the interferon signaling pathway interacting with other members of the IRF family like IRF1 and IRF3. These interactions help propagate signals necessary for effective immune responses. In conjunction with the JAK-STAT pathway IRF2 modulates expressions that control antiviral responses and cellular proliferation showing its critical placement in immune response regulation.

IRF2's dysregulation has associations with cancer and autoimmune diseases. Overexpression of IRF2 is linked to certain cancers providing cells with growth advantages and resistance to apoptosis commonly in concert with proteins like STAT1. In autoimmune diseases IRF2 impacts inflammatory responses with aberrant regulation contributing to conditions like systemic lupus erythematosus. Its involvement highlights the complex nature of immune regulation and potential for targeted therapy interventions.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 1 US: 1

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com